Year: 2026

Introduction Before a single carton of medicine ships to Lagos, Nairobi, or Accra, an Indian exporter needs a specific stack of licenses in place at home — separate from whatever registration the destination country requires. Getting a pharma export license India to Africa deals with isn’t one document, but a layered set of approvals from DGFT, the state drug authority, and CDSCO, each serving a different regulatory purpose. This guide walks through exactly what’s needed on the Indian side, step by step, before a product is even ready to begin NAFDAC, PPB, or FDA Ghana registration on the African side. Why This Is a Layered Process, Not One License Unlike many product categories, pharmaceuticals require export approval at two separate levels in India: a general trade-level authorization that applies to any exported goods, and a pharma-specific regulatory layer governed by the Drugs and Cosmetics Act. Key reasons the process has multiple layers: An IEC (Importer Exporter Code) is a general business requirement for any Indian company engaged in import or export, and is not specific to pharmaceuticals. A drug export licence, issued under the Drugs and Cosmetics Act by CDSCO or the State Drug Controller, is specific to pharmaceutical products and required in addition to the IEC. Certain products or destination countries may trigger additional CDSCO-specific approval requirements beyond the base export license Each license serves customs, quality-control, and international-compliance purposes independently Licenses and Registrations Required 1. Import Export Code (IEC) Issued by the Directorate General of Foreign Trade (DGFT), this is mandatory for all exports regardless of product category — the foundational registration needed before any export business can legally operate. 2. Drug Manufacturing / Wholesale License Issued under the Drugs and Cosmetics Act, 1940, this confirms the exporting entity is authorized to manufacture or deal in pharmaceutical products domestically — a prerequisite for pharma-specific export activity. 3. Drug Export NOC (No Objection Certificate) Granted by CDSCO or the State Licensing Authority, this NOC allows Indian manufacturers to legally export pharmaceutical products abroad, covering approved, unapproved, and banned drug categories depending on the case. Manufacturers must hold a valid license under Form 25 or 28 and comply with quality control standards to apply, with the application requiring an export order, covering letter, purchase order, manufacturing license, and invoice. 4. Certificate of Pharmaceutical Product (COPP) Exporters must obtain a COPP issued by CDSCO for each pharmaceutical product intended for export, certifying that the product is manufactured in compliance with Indian regulatory standards.</cite> This is the document African regulators (NAFDAC, PPB, FDA Ghana) will require as part of their own product registration process. 5. Free Sale Certificate (FSC) Exporters may also be required to provide an FSC issued by CDSCO, attesting to the product’s free-sale status in India. 6. GMP Certification This ensures manufacturing follows WHO Good Manufacturing Practices — increasingly a baseline expectation from African buyers and regulators alike, not just a nice-to-have. 7. GST Registration Required for export compliance, with exports treated as zero-rated under GST. Step-by-Step Process Step 1: Register for an IEC Apply through DGFT — this is the starting point for any export activity and typically the fastest of the required registrations. Step 2: Confirm Your Manufacturing/Wholesale Drug License Is Current This should already be in place for any operating pharmaceutical manufacturer, but confirm it covers the specific product categories you intend to export. Step 3: Apply for the Drug Export NOC Submit the export order, manufacturing license, invoice, and supporting documents to CDSCO or your State Licensing Authority. Step 4: Obtain COPP and FSC for Each Product These are issued per product, not per company — budget time for this on a product-by-product basis as you expand your export catalog. Step 5: Confirm GMP Certification Status Ensure your manufacturing site’s WHO-GMP certification is current, since this underpins COPP issuance and is frequently required directly by African regulators too. Step 6: Proceed to Destination-Country Registration With IEC, drug license, NOC, COPP, and FSC in place, you’re positioned to begin the separate registration process with NAFDAC, PPB, or FDA Ghana for your target African market. Common Mistakes That Delay the Process Treating the IEC as Sufficient on Its Own The IEC gets you export-eligible as a business, but pharmaceutical products still need the drug-specific NOC, COPP, and FSC layered on top. Applying for COPP/FSC Too Late Since African regulators require these as part of their own registration dossiers, delays here cascade directly into delays on the NAFDAC, PPB, or FDA Ghana side. Inconsistent Documentation Across Licenses Product names, manufacturing site details, and specifications should match exactly across the IEC, drug license, NOC, and COPP to avoid queries at any stage. Assuming One-Time Approval Covers All Products COPP and FSC are typically product-specific and time-bound, requiring renewal and reapplication as your export portfolio grows. Tips for a Smoother Process ✔ Sequence your applications — IEC first, then drug-specific approvals — rather than trying to parallel-process everything at once ✔ Apply for COPP and FSC for new products well ahead of any African market registration timeline, since those documents feed directly into NAFDAC/PPB/FDA Ghana applications ✔ Keep WHO-GMP certification current across your facility, since it underlies most of the downstream approvals ✔ Maintain a master compliance file per product covering every Indian-side document, to keep information consistent when it’s reused in destination-country dossiers Conclusion A pharma export license India to Africa route requires isn’t a single certificate — it’s a sequence of India-side approvals (IEC, drug license, export NOC, COPP, FSC) that together make a product export-ready, before destination-country registration with NAFDAC, PPB, or FDA Ghana even begins. Exporters who treat this as a structured sequence, rather than a single application, move products to market faster and with far fewer compliance surprises. Partnering with an experienced Pharma export company in India that has these approvals in place across a broad product portfolio removes much of this groundwork for African buyers and distributors.

Introduction Kenya’s public and private healthcare system continues to face real gaps in oncology drug availability — cancer patients in oncology wards have gone without treatment cycles when specific agents run short at the national level, and many patients end up sourcing cancer medicines themselves due to local stockouts. For hospitals, distributors, and even patients trying to import oncology drugs India manufacturers produce, understanding the legal, safe pathway matters as much as finding a supplier. India is a major global supplier of WHO – Generic medicines, including oncology products, making it an important sourcing market for Kenyan pharmaceutical buyers., making it a natural sourcing destination for Kenyan buyers. Manufacturers like Salvavidas Pharma, based in Surat, India, specialize in oncology and anti-HIV products specifically for export to African markets. This guide covers how that import process actually works — and just as importantly, how to avoid the risks that come with sourcing cancer drugs through unverified channels. Why Kenyan Buyers Look to India for Oncology Drugs Kenya’s cancer drug supply challenges are well documented in oncology wards, patients have missed treatment cycles because drugs such as Goserelin and Rituximab were not procured in tim, part of a broader supply chain crisis affecting multiple hospital-level medicine categories. Separately, patients often import cancer drugs — especially targeted therapies — due to local stockouts or perceived cost concerns, sometimes without verifying the source. India’s generic oncology manufacturing base offers a legitimate alternative, but only when sourced through the proper regulatory channels rather than informal or unverified routes. The Right Way vs. the Risky Way to Import This distinction matters more for oncology drugs than almost any other category, given the direct clinical consequences of substandard product. The risky path: Individual or informal sourcing of cancer drugs without verifying manufacturer credentials, storage conditions, or the product’s PPB registration status. Some oncology medicines require controlled temperature storage and transportation, depending on the individual product’s approved storage conditions. Exporters and buyers should follow the manufacturer’s specified storage and transport requirements throughout the supply chain. — under-dosing or overdosing from compromised product can force patients into additional costs from ineffective treatment or managing severe toxicities. The correct path: Importing through a PPB-registered channel, from a WHO-GMP certified Indian manufacturer, with full documentation and proper temperature-controlled logistics — whether you’re a hospital, distributor, or institutional buyer. What’s Required to Import Oncology Drugs from India to Kenya 1. PPB Product Registration The oncology product must be registered with Kenya’s Pharmacy and Poisons Board before it can be legally imported or distributed — this is non-negotiable regardless of the product’s approval status in India or elsewhere. 2. PPB Import Permit Importers and other regulated entities must meet the applicable PPB licensing and import requirements. Where an import permit is required, the shipment must be supported by the appropriate authorization before importation. 3. Local Authorised Representative (LAR) Indian manufacturers exporting to Kenya typically need a Kenya-based representative or distributor to manage registration and import permit applications on their behalf. 4. Certificate of Pharmaceutical Product (COPP) and GMP Certification Certificate of Pharmaceutical Product (COPP) and GMP CertificationDepending on the product and regulatory pathway, Kenyan registration documentation may require a Certificate of Pharmaceutical Product (COPP) and evidence of compliance with applicable GMP requirements. Indian manufacturers should maintain current regulatory certificates issued by the appropriate authorities. 5. Validated Cold Chain Logistics Temperature-sensitive specialty medicines require validated storage at origin and qualified shipping containers for the transit route, with evidence of Good Distribution Practice maintained across the entire journey expected by PPB and port health authorities. Many oncology drugs fall into this temperature-sensitive category. 6. Named Patient / Emergency Import Route (Where Applicable) Not every clinically needed medicine is registered in Kenya — specialty oncology agents and rare disease treatments sometimes require a named-patient import pathway as an alternative to standard commercial registration, used for individual patient access rather than bulk distribution. How the Process Typically Works Step 1: Identify a WHO-GMP Certified Indian Manufacturer Verify the manufacturer’s certifications and export track record before engaging further. Step 2: Confirm PPB Registration Status Check whether the specific oncology product is already PPB-registered, or whether registration needs to be initiated — this affects timeline significantly. Step 3: Engage a Local Authorised Representative Required to manage the Kenya-side registration and import permit process. Step 4: Apply for the Import Permit The local agent applies for the permit through the PPB portal, and the consignment is declared through the single window system, matched against the import permit before customs release. Step 5: Arrange Validated Cold Chain Shipping Coordinate temperature-controlled logistics appropriate to the specific product’s stability requirements. Step 6: Customs Clearance and Port Health Verification Final release requires the import permit, registration documentation, and evidence of maintained cold chain integrity. What to Verify Before Choosing a Supplier ✔ WHO-GMP or equivalent certification on the manufacturing facility ✔ Established export track record, ideally with prior shipments into East Africa specifically ✔ PPB registration status of the exact product and formulation you need ✔ Cold chain capability, verified rather than assumed, for temperature-sensitive oncology products ✔ Transparent documentation — COPP, CoA, and GMP certificates provided without hesitation Conclusion For Kenyan hospitals, distributors, and institutional buyers looking to import oncology drugs India manufacturers produce, the opportunity is real — India’s generic oncology sector offers quality treatment at costs that matter for a healthcare system already under supply pressure. But given the clinical stakes involved, the registered, PPB-compliant import pathway is the only responsible route, not an informal or unverified one. Salvavidas Pharma, a WHO-GMP certified pharmaceutical manufacturer and exporter based in Surat, India, specializes in oncology and anti-HIV products alongside a broader generics portfolio, with established export experience into African markets. Working with an experienced partner like Salvavidas Pharma — one with certified oncology manufacturing, a track record of compliant exports, and validated cold chain logistics — can make this process considerably more reliable for Kenyan buyers navigating real supply gaps.

Introduction For exporters targeting Ghana, the Ghana Essential Medicines List (EML), developed within Ghana’s Ministry of Health framework, is a useful reference point alongside FDA Ghana product registration. While FDA Ghana registration addresses the regulatory requirements for pharmaceutical products entering the market, the EML provides a reference for medicines used within Ghana’s healthcare system, including those considered under the National Health Insurance Scheme (NHIS). This guide covers how Ghana’s EML is structured and what it means for exporters planning market entry. What Is the Ghana Essential Medicines List? Essential medicines are those that satisfy the priority healthcare needs of the population, selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness. Ghana’s EML is derived from its companion Standard Treatment Guidelines, ensuring harmony between clinical treatment, procurement, and reimbursement decisions. The list uses the Recommended International Non-proprietary Name (rINN) for all medicines, in line with WHO recommendations and practice a detail worth noting for exporters preparing product documentation and labeling for the Ghanaian market. Important distinction for exporters: the EML is separate from FDA Ghana product registration. FDA registration and the accompanying import permit are what legally allow a specific product into Ghana. The EML instead reflects what the public health system is structured to procure, prescribe, and — critically in Ghana’s case — reimburse through NHIS. How Ghana’s EML Is Structured Ghana’s EML has two structural features that distinguish it from Nigeria’s and Kenya’s essential medicines lists, both worth understanding before entering the market. Facility-Level Coding Medicines are grouped by the facility level at which they can be prescribed and dispensed: Level A (Community), Level M (Midwifery), Level B1 (Health Centre without Doctor), Level B2 (Health Centre with Doctor), Level C (District Hospital), Level D (Regional/Teaching Hospital), Level SD (Specialist Drugs), and Level PD (Programme Drugs). Specialist Drugs are restricted to use by qualified specialists, while Programme Drugs are used specifically within Ministry of Health public health programmes and their guidelines. This matters directly for exporters: a product’s facility-level classification affects which type of buyer — community clinic, district hospital, or teaching hospital — will realistically be procuring it. NHIS Reimbursement Status Medicines are also marked as either reimbursed (R) or not reimbursed (NR) by the National Health Insurance Authority, based on the NHIS benefits package. A product’s reimbursement status has a direct effect on procurement volume, since NHIS-reimbursed medicines see substantially higher institutional demand than non-reimbursed equivalents. Key Therapeutic Categories on the EML While the exact category count varies by edition, the EML follows the WHO Model List structure, with categories most relevant to exporters including: 1. Anti-Infective Medicines Antibiotics, antimalarials, and antiviral agents — consistently the highest-volume category given Ghana’s infectious disease burden. 2. Anti-HIV / Antiretroviral Medicines Tied to Ghana’s national HIV treatment program and typically NHIS-reimbursed given their public health priority status. 3. Maternal and Child Health Medicines Includes midwifery-level (Level M) medicines specifically, reflecting Ghana’s facility-level structure for maternal care access. 4. Medicines for Non-Communicable Diseases A growing category as Ghana’s disease burden shifts toward chronic conditions alongside infectious disease. 5. Specialist and Programme Drugs Restricted-use categories (Level SD and PD) covering complex conditions and Ministry of Health public health programmes specifically — relevant for exporters supplying more specialized or programmatic products. Why the EML Matters for Exporters ✔ NHIS reimbursement status affects real demand A product’s R/NR marking has a direct bearing on how much institutional buyers will actually order — worth checking before prioritizing a product for Ghana. ✔ Facility-level coding shapes buyer targeting Understanding whether a product is classified for community, district, or specialist-level use helps target the right distributor and institutional relationships. ✔ rINN naming affects documentation Product naming across FDA registration documents and marketing materials should align with rINN conventions used in the EML. ✔ Distinct from, but complementary to, FDA registration An EML-aligned, NHIS-reimbursed product still requires full FDA Ghana registration and import permit — both processes matter independently. How Exporters Can Use This Information ✔ Check NHIS reimbursement status for target products before prioritizing them for the Ghanaian market✔ Align product naming and documentation with rINN conventions used in Ghana’s EML and Standard Treatment Guidelines✔ Match your product’s facility-level classification to the right type of distributor or institutional buyer relationship✔ Prioritize FDA Ghana registration for products in high-reimbursement, high-priority EML categories Conclusion Ghana’s EML stands out for its facility-level coding and NHIS reimbursement structure — details that directly shape which buyers will procure a given product and at what volume. Exporters who understand this structure, on top of securing FDA Ghana registration and import permits, are better positioned to match their product portfolio to how Ghana’s healthcare system actually buys. Partnering with an experienced pharma export company in India familiar with both FDA Ghana requirements and EML/NHIS structures helps align product strategy with actual market demand rather than guesswork.